NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: UMIN000002618

Registered date:31/03/2010

Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedSmall-cell lung cancer
Date of first enrollment2008/09/01
Target sample size30
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Amrubicin and carboplatin

Outcome(s)

Primary OutcomeResponse rate
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximumNot applicable
GenderMale and Female
Include criteria
Exclude criteria1. Severe co-morbidities 2. Symptomatic brain metastasis 3. Massive effusion that require drainage 4. Pregnant woman

Related Information

Contact

public contact
Name
Address Japan
Telephone
E-mail akinoue@idac.tohoku.ac.jp
Affiliation Tohoku University Hospital Department of Respiratory Medicine
scientific contact
Name Akira Inoue
Address 1-1, Seiryomachi, Aobaku, Sendai Japan
Telephone
E-mail
Affiliation Tohoku University Hospital Department of Respiratory Medicine